Vice President of Business Development
Michael Lebel joined Casma in 2019 from Celgene. He joined Celgene when they acquired Avila Therapeutics. Mike worked at Celgene for more than seven years, where he was responsible for leading collaborations, licensing transactions, making equity investments, and mergers and acquisitions across a variety of therapeutic areas. Mike’s transactions and collaborations have spanned the spectrum from early research agreements to late stage development and commercialization deals and included companies such as Agios Pharmaceuticals, Juno Therapeutics, Sutro Biopharma and Vividion Therapeutics. At Avila, Mike was the executive director for business development and global alliances. Earlier in his career, Mike spent time at Momenta Pharmaceuticals as the Alliance head for their collaboration with Sandoz on the enoxaparin and glatiramer acetate development programs. Both agents were approved.
Mike has a Bachelor of Science degree in biochemistry from the University of Maine, and a Master of Business Administration from Suffolk University in Boston
Why Casma, Why Me?
For me, Casma was the perfect fit, the right mix of great science combined with great people!